Clinical Trials on Neuroendocrine Tumor Grade 3 in Netherlands

Total 255 results

Novartis Pharmaceuticals

Completed

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Pancreatic Neuroendocrine Tumors (pNET)

France, Spain, Belgium, Germany, Italy, United Kingdom, Austria, Netherlands, United States
Paola Anna Erba
Erasmus Medical Center; Jagiellonian University; Medical University Innsbruck; University... and other collaborators

Completed

Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC (GRAN-T-MTC)

Medullary Thyroid Carcinoma

Austria, Germany, Netherlands, Poland, Slovenia
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
University Medical Center Groningen

Recruiting

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (POINTING)

Melanoma | Non-Small Cell Lung Cancer

Netherlands
Leiden University Medical Center

Recruiting

PHP and Immunotherapy in Metastasized UM (CHOPIN)

Uveal Melanoma, Metastatic

Netherlands
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
Advanced Accelerator Applications

Completed

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Gastroenteropancreatic Neuroendocrine Tumors

United Kingdom, Italy, Netherlands, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
University Medical Center Groningen

Completed

Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors

Melanoma | Non Small Cell Lung Cancer

Netherlands
Marnix Lam

Completed

Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases (LUTIA)

Neuroendocrine Tumors | Liver Metastases

Netherlands
Pfizer

Completed

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

Locally Advanced or Metastatic NRAS Mutant Melanoma

United States, Australia, Germany, Italy, Netherlands
Azienda Ospedaliera di Perugia

Not yet recruiting

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients (MELCAYA)

Advanced Melanoma | Early Melanoma

Italy, Sweden, France, Germany, Netherlands, Poland, Spain
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors (pNET)

United Kingdom, Spain, Netherlands, Italy, Russian Federation, France, Switzerland, United States
Jasper Gerritsen
University Medical Center Groningen; University Hospital, Ghent; Medical Center... and other collaborators

Recruiting

The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. (SAFE)

Glioblastoma | Brain Neoplasms | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | Astrocytoma, Grade IV | Glioblastoma Multiforme of Brain

Netherlands, Belgium
European Organisation for Research and Treatment...
Tragara Pharmaceuticals, Inc.

Completed

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM)

Glioblastoma | Astrocytoma, Grade III

France, Austria, Germany, Netherlands, Switzerland
Paul G. Kemps, MD
Juliana Children's Hospital

Active, not recruiting

GastroIntestinal Cancer in Children and Adolescents (GICCA)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Burkitt Lymphoma | Neuroendocrine Tumors | Gastrointestinal Cancer | Hepatoblastoma

Netherlands
National Cancer Institute (NCI)

Unknown

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Lung Cancer | Metastatic Cancer | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

Spain, United Kingdom, Germany, Netherlands, Israel, Sweden, Poland, Denmark, Greece, Italy
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor

France, Germany, Italy, Netherlands, Sweden, United Kingdom, Brazil, Israel, Korea, Republic of, United States
Vastra Gotaland Region

Recruiting

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NivoILP)

Melanoma | In-Transit Metastasis

Sweden, Netherlands
Novartis Pharmaceuticals

Completed

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Uveal Melanoma

United Kingdom, France, Netherlands, United States
Maastricht Radiation Oncology
Maastricht University Medical Center

Recruiting

Vestibular Schwannoma Organoids

Vestibular Schwannoma

Netherlands
Genzyme, a Sanofi Company
Worldwide Clinical Trials

Completed

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

Symptomatic, Aggressive, Sporadic, Unresectable, Locally | Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Belgium, Italy, Netherlands, Spain, France, Germany, United Kingdom, Luxembourg
Novartis Pharmaceuticals

Completed

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Acromegaly | Carcinoid Tumor

Germany, Belgium, Canada, Netherlands, United States, Norway
University Medical Center Groningen

Terminated

[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis

Melanoma

Netherlands
European Organisation for Research and Treatment...

Active, not recruiting

Minimal SN Tumor Burden (Minitub)

Cutaneous Melanoma

France, Italy, Switzerland, Belgium, Netherlands, Germany, Poland, Slovenia, United Kingdom, Spain
Bristol-Myers Squibb

Completed

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Melanoma

Italy, Netherlands, Russian Federation, Czechia, Hungary, Ireland, Norway, Spain, Switzerland, Austria, Germany, Denmark, France, Belgium, United Kingdom, United States
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
Array Biopharma, now a wholly owned subsidiary...

Terminated

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Uveal Melanoma

United States, France, Germany, Netherlands, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
Array BioPharma

Terminated

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Locally Advanced Metastatic BRAF Mutant Melanoma

Australia, Canada, Netherlands, United States
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
ITM Solucin GmbH
ABX CRO; PSI CRO

Active, not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Neuroendocrine Tumors

Germany, France, United States, United Kingdom, Australia, Italy, Belgium, Switzerland, Czechia, Spain, Austria, Netherlands, Poland, South Africa
University Medical Center Groningen

Terminated

Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (CA209-322)

Melanoma | Brain Metastasis

Netherlands
Grupo Espanol de Tumores Neuroendocrinos
Novartis Pharmaceuticals; European Neuroendocrine Tumor Society; Kantar Health

Completed

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (SEQTOR)

Neuroendocrine Tumors

Spain, United Kingdom, Denmark, France, Netherlands, Germany, Italy, Sweden
Radboud University Medical Center
The Netherlands Cancer Institute; Isala

Recruiting

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COWBOY)

Melanoma, Malignant, of Soft Parts

Netherlands
Saint John's Cancer Institute
Melanoma Research Alliance

Terminated

Stage IV Surgery Versus Best Medical Therapy (STG4SURG)

Stage IV Resectable Melanoma

United States, Australia, Israel, Italy, Netherlands
Maastricht University Medical Center

Recruiting

Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs

Recurrence | Complication of Surgical Procedure | Skin Cancer | Recurrent Disease | Complication | Complication,Postoperative | Lentigo Maligna Melanoma | Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Lentigo Maligna

Netherlands
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)

Melanoma

United States, Italy, United Kingdom, Netherlands, Canada, Germany, Australia, Spain, Switzerland, France
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; European Network of Gynaecological Oncological Trial... and other collaborators

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)

Low Grade Serous Ovarian Carcinoma | Adult Type Granulosa Cell Tumor

Belgium, Netherlands, France
University Medical Center Groningen

Completed

Pembrolizumab-PET Imaging

Melanoma | Non-small Cell Lung Cancer

Netherlands
Melanoma and Skin Cancer Trials Limited
Melanoma Institute Australia; Cancer Council New South Wales

Active, not recruiting

Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma (EAGLE FM)

Metastatic Melanoma to the Groin Lymph Nodes

United Kingdom, Slovenia, Australia, Brazil, Netherlands, Italy
AstraZeneca

Completed

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Melanoma

Sweden, United States, Brazil, Czech Republic, France, Spain, United Kingdom, Germany, Norway, Hungary, Netherlands, Switzerland
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

France, Switzerland, Germany, Belgium, Netherlands, United Kingdom, Italy, Portugal, Austria
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine

Clinical Trials on Neuroendocrine Tumor Grade 3 in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations